California to Sell Affordable Insulin Starting January
On Thursday, Governor Gavin Newsom shared that California will sell its own brand of affordable insulin starting January 1. This initiative comes almost three years after the state first revealed plans to provide state-branded generic drugs at lower prices.
However, California isn’t standing alone in this effort. Civica, a nonprofit organization, has also announced that it will be distributing affordable diabetes medications nationwide. The partnership between California and Civica on the CalRx brand of insulin began in 2023, with the organization investing $50 million into its development.
Come the new year, insulin pens will be priced at a recommended $11 each, or $55 for a pack of five, as per Civica’s announcement.
“There’s no need for a new prescription,” Newsom explained during a news conference in Los Angeles. “It’s about making this accessible and affordable.”
This initiative is part of California’s broader strategy to cut down prescription drug costs by providing cheaper alternatives. Earlier in April, Newsom had announced plans to sell naloxone, an important drug for combating the overdose crisis, in both nasal spray and injection forms.
For the development of insulin, a 10-year agreement was established with Civica and Biocon Biologics in early 2023. Officials believe that California’s entry into the insulin market might lead to a significant drop in prices.
The new insulin pen is compatible with glargine, which is a generic version of a more expensive daily injection that helps manage blood sugar. For context, a pack of five Eli Lilly’s Lesvogral is priced over $88 in pharmacies, though costs can vary based on insurance.
According to the American Diabetes Association, around 38 million Americans and 3.5 million Californians are living with diabetes.
Chris Noble, who directs Health Access California, expressed support for Newsom’s announcement and noted that efforts to develop competitive generic drugs will be a relief for patients facing high drug prices. “California consumers need relief now,” he said, praising CalRx for moving swiftly to help reduce insulin costs while additional solutions are sought.
That said, there are potential risks involved. State analysts have cautioned that California’s new role in the market might lead some manufacturers to limit drug availability, potentially causing unforeseen problems.
The state Legislature allocated $100 million for this initiative in 2022, with half of that specifically for developing three types of insulin and the rest earmarked for manufacturing investments.
Documents from 2023 suggest that the program could save patients between $2,000 and $4,000 a year. Plus, with states purchasing insulin for many publicly funded health plan enrollees, lower costs could lead to significant overall savings.
